

Cover Story
Guest Editorial
As the world faced the threat of a novel respiratory pathogen, SARS-CoV-2, in the first months of 2020, there was a great deal of uncertainty about its effect on people, especially those living with a diagnosis of cancer.
In Brief


Clinical Roundup


Drugs & Targets


Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”
- Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)
- As more people are surviving cancer, we must continue funding bold science
- One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- CBER Director Vinay Prasad dared to “say no to drugs”














